This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Chronic myelogenous leukemia (CML)	BCR-ABL tyrosine kinase	<p>Cell culture studies suggest Bosulif bosutinib plus danusertib could help treat CML resistant to Gleevec imatinib. In primary cancer cells isolated from a patient with Gleevec-resistant CML, bosutinib and danusertib synergistically decreased cell proliferation compared with vehicle. The combination did not show a synergistic antiproliferative effect in cells from a patient with Gleevec-sensitive CML. Next steps could include testing the combination in a mouse model of Gleevec-resistant CML.</p> <p>Novartis AG markets the BCR-ABL inhibitor Gleevec to treat CML and gastrointestinal stromal tumors (GISTs).</p> <p>Pfizer Inc.'s Bosulif, a dual inhibitor of BCR-ABL and Src, is approved to treat CML.</p> <p>Nerviano Medical Sciences s.r.l.'s aurora kinase inhibitor, danusertib (PHA-739358), is in Phase I and Phase II testing to treat various cancers.</p> <p>SciBX 5(42); doi:10.1038/scibx.2012.1106 Published online Oct. 25, 2012</p>	Patent and licensing status unavailable	<p>Winter, G.E. <i>et al. Nat. Chem. Biol.</i>; published online Sept. 30, 2012; doi:10.1038/nchembio.1085</p> <p>Contact: Giulio Superti-Furga, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria e-mail: gsuperti@cemm.oeaw.ac.at</p>